A new spectrofluorimetric assay method for vandetanib in tablets, plasma and urine by Darwish, Hany W. & Bakheit, Ahmed H.
Darwish & Bakheit 
Trop J Pharm Res, October 2016; 15(10): 2219  
 
Tropical Journal of Pharmaceutical Research October 2016; 15 (10): 2219-2225 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v15i10.21 
Original Research Article 
 
 
A new spectrofluorimetric assay method for vandetanib in 
tablets, plasma and urine 
 
Hany W Darwish1,2 and Ahmed H Bakheit1 
1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457 Riyadh, 11451, Kingdom 
of Saudi Arabia, 2Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt 
 
*For correspondence: Email: hdarwish75@yahoo.com; Fax: +966 1146 76 220 
 
Received: 24 May 2016        Revised accepted: 11 September 2016 
 
Abstract 
Purpose: To develop a simple and sensitive spectrofluorimetric method for the determination of 
vandetanib (VDB) in tablets (containing 100 mg of the drug) and biological fluids (spiked human plasma 
and urine).  
Methods: The proposed method is based on examining the intrinsic fluorescence intensity of VDB in 
acetonitrile at 480 nm after excitation at 330 nm. Factors affecting fluorescence intensity of the cited 
drug (VDB), including the influence of pH, diluting solvent and time, were studied and optimized by one 
factor at a time approach. A calibration curve was constructed by plotting VDB fluorescence intensity at 
480 nm versus VDB concentrations in ng mL-1. The method was validated according to the 
recommendations of International Conference on Harmonisation (ICH) for validation of the analytical 
procedures     
Results: The linearity range of the method was 20 – 600 ng mL-1, with limits of quantification (LOQ) and 
of detection (LOD) of 30.45 and 10.05 ng mL-1, respectively. The adopted method was applied 
successfully to the quantitation of VDB in pure powder form (100.90 ± 0.91 %), laboratory prepared 
tablets (97.86 ± 1.42 %), spiked human plasma (97.97 ± 2.36 %) and urine (97.59 ± 0.87 %). 
Comparison of the proposed method with that of liquid chromatography-tandem mass spectrometry 
showed that there was no significant difference (p < 0.05) between the two methods in terms of 
accuracy and precision. 
Conclusion: The proposed method is simple and highly sensitive and, consequently, can be applied to 
assay VDB in biological samples as well as in dosage form.  
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Vandetanib (VDB) is considered one of the novel 
tyrosine kinase inhibitors (TKIs) that acts by 
inhibiting numerous receptors of the human cell 
such as RET-tyrosine kinase, epidermal growth 
factor receptor and others [1,2]. It is prescribed 
for treating progressive or symptomatic 
medullary carcinoma of thyroid glands. The 
effectiveness of VDB for treating ER negative 
breast cancers was also suggested by modern 
preclinical researches [3]. Moreover, VDB could 
be used solely or in combination with other 
treatment regime such as chemotherapy or 
radiotherapy for   managing other kinds of tumors 
[4,5]. Consequently, it is expected that VDB will 
be widely spread as an effective anticancer in the 
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near future. The chemical structure of VDB is 




Figure 1: Chemical structure of vandetanib (VDB)  
 
Establishing simple and sensitive analytical 
method for quantitation of VDB in different 
matrices is very important as the therapeutic 
monitoring of a certain medication (VDB in our 
case) is relied upon the accurate analysis of this 
medication. Additionally, understanding the 
relationship between the concentration level and 
activity of VDB is crucial for its routine and safe 
usage by the patients. Spectrofluorimetric 
analysis characterized by various advantages for 
instance sensitivity and simplicity and wide 
availability of instrument in quality control 
laboratories [6,7]. For these advantages, this 
technique was adopted for developing a unified 
analytical method for quantitation of VDB in 
different matrices.  
 
Only a few published articles have been reported 
for VDB assay in plasma or other biological 
fluids. These analytical methods included liquid 
chromatographic methods coupled with; mass 
spectrometry [8-11], diode array [12] and UV 
detection [13]. The disadvantages of these 
methods are complexity, high cost and wasting of 
time in addition to laborious sample treatment. 
VDB assay in urine samples was reported by just 
one liquid chromatographic method coupled with 
mass spectrometry [9] while there are no 
previous reports, to the best of our knowledge, 
regarding the assay of VDB in tablets or pure 
bulk powder. Thus the aim of the present study 
was to develop a simple, sensitive and unified 
analytical method for the assay of VDB in various 






Fluorescence measurements were performed 
utilizing a Jasco FP-8200 Fluorescence 
Spectrometer (Jasco Corporation, Japan) 
equipped with a xenon lamp (150 W) and quartz 
cells (one cm). Excitation and emission slit 
widths for both monochromators were adjusted 
at 5 nm. Quinine sulphate (0.01 µg mL-1) was 
utilized for frequent calibration of Jasco FP-8200 
Spectrometer and the recorded spectra were 
transformed to ASCII format using Spectra 
Manager® software. 
 
Reagents and materials 
 
All the chemicals used in this study were of 
analytical reagents grade, and the solvents of 
HPLC grade. 
 
Vandetanib reference standard (purity ~ 99.5 %) 
was purchased from LC Laboratories (MA, USA). 
Methanol, ethanol (Prolabo, France) and 
acetonitrile (Sigma-Aldrich Chemie GmbH, 
Germany). Ultrapure water ≥ 18.2 MΩ was 
obtained from a Millipore Milli-Q® UF Plus 
purification system (Millipore, Bedford, MA, 
USA). Human plasma was kindly provided by 
King Khaled University Hospital (King Saud 
University, Riyadh, KSA). After informed consent 
was obtained, fasting blood samples were taken 
and plasma, separated and stored at -70 °C. 
 
Preparation of standard solutions 
 
VDB stock solution of 1 mg mL-1 was prepared 
by dissolving 25 mg of VDB reference standard 
powder into 25 mL of acetonitrile in a 25 mL 
measuring flask and completing the volume 
properly by the same solvent. VDB stock solution 
was further diluted with acetonitrile to yield a 
working standard solution of 1 μg mL-1. The 
standard solutions were stable for at least 14 
days when kept refrigerated at -4 oC. 
 
Construction of calibration graph 
 
Different volumes of VDB standard solution were 
transferred into a series of 5 mL volumetric flasks 
and diluted with acetonitrile to yield final 
concentrations of 20 – 600 ng mL-1. The contents 
of the flasks were well mixed and RFI of VDB 
was measured at 480 nm after excitation at 330 
nm. For generation of calibration curve, RFI at 
480 nm (as y axis) was plotted vs the final VDB 
concentration in ng mL-1 (as x axis) and then the 
regression equation was calculated. 
 
Assay of VDB tablet samples 
 
Preparation of tablets of VDB produced in-house 
(equivalent to 100 mg of the drug) took place 
through weighing precise amount of powder 
equivalent to 100 mg VDB and transferring it to a 
100 mL volumetric flask. Acetonitrile (50 µL) was 
then added and the contents were shaken and 
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sonicated for 10 and 5 min, respectively. 
Ultimately the volume was diluted to 100 mL with 
acetonitrile to get final concentration of 1 mg mL-
1. This solution was subsequently diluted by 
acetonitrile for further analysis.  
 
Assay of VDB in human plasma  
 
Liquid-liquid extraction was used for extraction of 
VDB from spiked plasma samples. Frozen 
Plasma samples (-20 oC) were thaw at room 
temperature before processing. Twenty 
microliters of standard VDB solutions (at different 
concentrations of the drug) was spiked into one 
mL of free drug human plasma and mixed well 
for one min to yield final spiked plasma 
concentrations of 200, 300 and 400 ng mL-1, 
respectively. One mL of 100 mM NaOH / glycine 
buffer (pH 12) was added and the tube was 
mixed properly for 10 s using vortex mixer. Five 
mL of diethyl ether was added and the solution 
was vortexed for 30 s and ultra-centrifuged for 15 
min at 10000 rpm to ensure complete phase 
separation. Afterwards three mL of the upper 
organic layer was taken to glass vials and dried 
under gentle stream of nitrogen. Ultimately, 
residue reconstitution took place in acetonitrile 
and the procedures depicted under “Construction 
of the calibration graph” were then followed. RFI 
was determined at 480 nm after excitation at 330 
nm and the concentration of the drug was 
calculated by substitution in the corresponding 
regression equation. A blank plasma sample was 
treated in a similar way. 
 
Assay of VDB in human urine  
 
Free drug human urine (1 mL) was spiked with 
twenty µL of standard drug solutions (at different 
concentrations of VDB) to yield concentrations of 
15, 25 and 75 µg mL-1, respectively and mixed 
for 60 s. Further dilution done by adding thirty µL 
from the prepared previous solution to a thirty 
microliters of 100 mM NaOH / glycine buffer (pH 
12) then the tube was vortexed for 10 s. 1250 µL 
of diethyl ether was added and the solution was 
vortexed for 30 s and ultra-centrifuged for 15 min 
at 10000 rpm to assure complete phase 
separation. Then one mL of the upper organic 
layer was transferred into glass vial and dried 
under a gentle stream of nitrogen. Finally, 
reconstitution of the residue occurred in 
acetonitrile and the procedures depicted under 
“Construction of the calibration graph” were then 
followed.  A blank urine sample was treated 
similarly. Fluorescence intensity was determined 
at 480 nm after excitation at 330 nm and the 
VDB concentration was calculated by substitution 
in its corresponding regression equation. 
 
Data analysis  
 
Analysis of data was carried out using Microsoft 
Excel-2007 software. Differences were 
considered statistically significant at p < 0.05. 
The data from fluorescence spectrometer were 




The fluorescence spectra of VDB in acetonitrile is 
illustrated in Figure 2. VDB, being a native 
fluorescent molecule, exhibited excitation and 




                          Figure 2: Excitation (1) and emission (2) spectra of VDB (400 ng mL-1) in acetonitrile 
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Effect of pH 
 
The effect of pH on the fluorescence intensity of 
VDB was carefully studied using different buffers 
covering the pH range of 2 - 12. It was observed 
that fluorescence intensity of VDB is not affected 
by adding any buffer. Thus, no buffer was added 
in the current work. 
 
Effect of diluting solvent and time 
 
The effect of addition of various diluting solvents 
for instance water, short chain alcohols 
(methanol and ethanol) and acetonitrile on the 
fluorescence intensity of VDB was evaluated 
(Figure 3). It was observed that acetonitrile gave 
the highest response while distinct and sharp 
decrease in VDB fluorescence intensity was 
observed on adding other solvents. Accordingly, 
acetonitrile was utilized for dilution purpose in the 
current method.  
 
Regarding time effect, it was found that VDB 
fluorescence intensity developed instantaneously 




Validation of the current spectrofluorimetric 
method was done in accordance with the 
recommendations of International Conference on 
Harmonisation (ICH) for validation of the 
analytical procedures [14]. 
 
Linearity and range 
 
Calibration curve for VDB assay was constructed 
under the optimum conditions by plotting VDB 
fluorescence intensity at 480 nm against the 
corresponding VDB concentration. The linearity 
range was found to be 20 - 600 ng mL-1 as 
shown in Table 1. 
 
Statistical analysis [15] of the experimental data 
displayed high correlation coefficients (r) values 
(approaching to unity) and low values of; 
intercept (Sa), slope (Sb), standard deviation of 
residuals (Sy/x), percentage relative error and 
percentage relative standard deviation (in Table 
1). These values established the linearity of VDB 
calibration curve. 
 
Limit of quantitation (LOQ) and limit of 
detection (LOD) 
 
Limit of quantitation and detection (LOQ and 
LOD respectively) were computed by measuring; 
the minimal concentration below which the 
calibration curve is nonlinear (for LOQ) and the 
minimal detectable VDB concentration (for LOD). 
The values of LOQ and LOD were calculated 
according to Eqs 1 and 2. 
 
LOD = 3.3ρ ……………………. (1) 
 
LOQ = 10ρ …………………….. (2) 
 
where ρ is the ratio of standard deviation of the 
intercept and the slope of regression line. The 
results are displayed in Table 1. 
 
Maximum concentration of VDB in plasma (Cmax) 
reported in the literature [9] is ranged from 117.3 
- 131.4 ng mL-1 which is greater than LOQ value 
(30.45 ng mL-1) and consequently quantitation of 
VDB can be done easily by the proposed 
spectrofluorimetric method. 
 
                       Figure 3: Effect of the diluting solvent on fluorescence intensity of VDB (400 ng mL-1) 
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Table 1: Analytical performance data for 
spectrofluorimetric determination of VDB 
 
Parameter VDB 
Wavelength [λex/ λem] (nm) 330/480 
Linearity range (ng/mL) 20-600 
Intercept (a) 7.10 
Slope (b) 0.890 
Correlation coefficient (r) 0.997 
S.D. of residuals (Sy/x) 11.20 
S.D. of intercept (Sa) 2.711 
S.D. of slope (Sb) 0.009 
% RSDa 1.337 
% Errorb 0.696 
LOD (ng/mL)c 10.05 
LOQ (ng/mL)d 30.45 
a %Relative standard deviation (n = 3);  b % Relative 
error (n = 3); c limit of detection; d limit of quantitation 
 
Accuracy and precision 
 
Table 2 presented results that verify the accuracy 
and precision of our suggested method. Intra-day 
and inter-day precision calculation involve the 
analysis of triplicate sample in one day and three 
successive days respectively.  
 
Recovery (% ± RSD) was utilized for stating 
intra-day and inter-day precisions. Low values of 
RSD and about 100% mean recovery% 
demonstrated intra and inter-day precisions of 
the adopted spectrofluorimetric method (Table 
2).  
Moreover, the comparison achieved between the 
results of determination of VDB in pure form with 
the results of VDB determination by the 
published LC-MS/MS method [8] showed the 
accuracy of the current proposed method. 
Computed F and t- values were smaller than the 
tabulated values at 95 % confidence level (Table 
3) which in turn confirmed that there is no 
significant differences between the two methods 




By analyzing laboratory prepared tablets of VDB 
(CAPRELSA™ tablets), it was clear from the 
results that the excipients did not interfere with 
VDB determination which reveal the specificity of 
the current method (Table 4). 
 












Recovery (% ± 
RSD) a 
40 39.59 98.97± 1.3 38.51 96.27± 1.36 
100 97.52 97.52±1.64 97.19 97.19± 1.00 
200 201.11 100.55± 1.1 198.73 99.36±1.69 
400 410.34 102.58± 0.81 392.98 98.24± 0.80 
a Mean of three determinations 
 
Table 3: Statistical comparison between analysis results of VDB in pure powder form by proposed 
spectrofluorimetric method and the reported method [8] 
 
Parameter Proposed method Reported method[8] 
Mean 100.93 100.17 
SD 2.458 1.355 
RSD% 2.453 1.353 
N 9 6 
Variance 6.042 1.836 
F value  3.291 (4.818) *  
T test  0.758 (2.160) *  
       * Tabulated value at p = 0.05 
 
Table 4: Results of the determination of VDB in pure form, laboratory made tablets, human plasma and human 




























100 99.88 99.88 198.24 99.12 200 99.88 15 98.17 
200 202.60 101.30 294.45 98.15 300 95.34 25 96.59 
400 406.28 101.57 385.28 96.32 400 98.70 75 98.00 
Mean   100.92  97.86  97.97  97.59 
± SD   0.91  1.42  2.36  0.87 
* Tabulated value at p = 0.05 
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Application of proposed method to assay of 
VDB tablets 
 
On application of the proposed method to VDB 
tablets, recovery of VDB in the tablets was 97.86 
 1.42 % which indicates good accuracy of the 
proposed procedure (Table 4). By comparing the 
results of bulk powder analysis in absence and 
presence of excipients found in VDB tablets, it 
can be seen that there is no significant difference 
in the two conditions in terms of accuracy and 
precision (Table 5). The excipients added are 
magnesium stearate, microcrystalline cellulose, 
crospovidone, povidone and calcium hydrogen 
phosphate dehydrate. 
 
Table 5: Statistical comparison between analysis 
results of VDB in presence and absence of 
pharmaceutical excipients by the adopted 
spectrofluorimetric method 
 
Sample no. VDB recovery (%) Absence Presence 
1 99.88 99.12 
2 101.3 98.15 
3 101.57 96.32 
Mean 100.92 97.86 
S.D. 0.91 1.42 
Variance 0.824 2.022 
Degree of  
freedom 4 
t-test (2.776)* 3.135 
F-test (19)* 2.453 
* Tabulated value at p = 0.05 
 
Application of proposed method to 
determination of VDB in human plasma 
 
The sensitivity of the adopted spectrofluorimetric 
method allowed us to quantify VDB in spiked 
human plasma. Maximum concentration of VDB 
in plasma attained after 6 h following oral 
administration [9] where its Cmax value was 131.4 
ngmL-1 under fasted circumstances [9]. Hence, 
level of VDB in plasma is involved in the linear 
range of the current procedure (Table 1). Table 5 
displayed mean recovery % and RSD% of VDB 
in spiked plasma samples (97.97 %, 2.36 % 
respectively).  
 
Application of proposed method to assay of 
VDB in urine 
 
In the first three days, VDB excreted in urine 
largely unchanged and ranged from 1.9 - 3.4 % 
of normal adult dose (300 mg daily) [9]. 
Consequently, the range of VDB concentration in 
urine (1.9 - 3.4 µg mL-1) is above the linear range 
of the current procedure. Mean recovery and 
RSD for VDB in urine samples were 97.59, and 
0.87 %, respectively. 
DISCUSSION 
 
In this study, a unified procedure was proposed 
for determination of VDB in different matrices 
including pharmaceutical preparation, human 
plasma and urine. Upon examination of literature, 
it was observed that few analytical methods were 
reported for VDB determination. Accordingly, a 
simple and sensitive spectrofluorimetric method 
was developed in the current work for VDB 
quantitation in these different matrices. 
Generally, the fluorescence spectrum of a native 
fluorescent drug composed of two spectra, the 
first spectrum associated with the excitation 
behavior of the drug while the other one 
associated with its emission of the absorbed 
electromagnetic radiation (EMR). Excitation 
spectrum is acquired by scanning excitation 
monochromator and fixing emission 
monochromator at a certain wavelength. The 
emission spectrum is acquired similarly, but 
scanning the emission monochromator and fixing 
the excitation monochromator at a particular 
wavelength. Therefore, for a fluorescent drug, 
two wavelengths are detected where highest 
response observed in the excitation and 
emission spectra (λex and λem, respectively). 
 
The principal demand for a drug to produce a 
fluorescence spectrum is to absorb EMR. VDB 
displays an excitation wavelength of 330 nm. 
This is due to absorption of EMR encouraging 
electron from its ground state to the excited 
state. The emission spectrum of VDB was then 
measured (utilizing concentration of 400 ng mL-1) 
keeping the excitation monochromator at 330 nm 
and scanning the emission monochromator in the 
range of 300 – 600 nm. Highly intense emission 
peak with maximum at 480 nm was observed, 
demonstrating the native fluorescence behaviour 
of VDB. Then the excitation spectrum was 
recorded, but now keeping the emission 
monochromator at 480 nm and scanning the 
excitation monochromator to precisely detect λex 
which observed at 330 nm. 
 
Various parameters that may influence 
fluorescence intensity of VDB were adjusted 
carefully adopting changing one factor at a time 
strategy. From the previous results it was clear 
that the most effective parameter was the diluting 
solvent. Acetonitrile was chosen for conducting 
this study as it gave the highest fluorescence 
intensity. This may be due to alteration of the 
polarity of the medium which could result in 
physical interaction between the excited singlet 
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The developed spectrofluorimetric method is 
simple, sensitive and can be applied successfully 
to VDB quantitation in quality control and clinical 
laboratories. The method offers several 
advantages over published chromatographic 
methods for VDB determination, including 
simplicity, rapidity and low cost. Additionally, the 
method is based on measuring the native 
fluorescence property of VDB and thus, there is 
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